Regulus Therapeutics Will Advance To Third Cohort Of Patients In The Phase 1B Mad Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease; Patients In The Third Cohort Will Receive 3 mg/kg Of RGLS8429 Or Placebo Every Other Week For Three Month
Portfolio Pulse from Benzinga Newsdesk
Regulus Therapeutics is advancing to the third cohort of patients in the Phase 1B Mad Study of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease. Patients in this cohort will receive 3 mg/kg of RGLS8429 or a placebo every other week for three months.
October 19, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics' advancement to the third cohort in the Phase 1B Mad Study of RGLS8429 could potentially impact the company's stock positively if the results are favorable.
The advancement of RGLS8429 to the third cohort in the Phase 1B Mad Study indicates progress in the drug's development. If the results from this cohort are positive, it could potentially lead to a boost in Regulus Therapeutics' stock as it would indicate the drug's potential for success in later stages of clinical trials and eventual market approval.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 100